Lilly’s pipeline drug retatrutide sets new threshold for weight loss at medical meeting reveal
Eli Lilly’s experimental weight loss drug appears to have set a new bar, helping obese patients in a Phase II study lose 24% of their body weight after about a year of treatment.
The drop in weight translated to an average of 58 pounds for patients on the highest dose of the drug, according to data presented Monday at the American Diabetes Association conference in San Diego. It’s an effect that easily beats other similar weight loss drugs in pharma pipelines or already on the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
